The US Food and Drug Administration approved Medtronic's plan for a feasibility trial of its Intrepid transcatheter valve replacement system for treating tricuspid regurgitation, the company announced on 9 September.
The FDA also granted Intrepid its breakthrough device designation, indicating the agency believes the device could provide important clinical benefits to a patient population that does not currently have many...